Business
Regeneron Pharmaceuticals discovers, develops and markets biologic medicines.
Regeneron Pharmaceuticals: Revenue grew 1.0% to $14.343B from $14.202B. Net income grew 2.1% to $4.505B from $4.413B. Free cash flow grew 11.3% to $4.08B from $3.665B. Operating margin contracted 315 bps to 24.95%. Regeneron Pharmaceuticals's annual comparison also shows capital spending grew faster than revenue; inventory grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 1.0%OK
- Profitability — Net income grew 2.1% to $4.505B from $4.413BOK
- Cash flow — Free cash flow grew 11.3% to $4.08B from $3.665BOK
- Margins — Operating margin contracted 315 bps to 24.95%Watch
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 10 salesWatch
Where the revenue comes from
Fiscal 2025, as REGENERON PHARMACEUTICALS, INC. reports it. History and quarterly detail are in the app.
- Collaboration revenue$7.3B
- Net product sales$6.3B
- Regeneron's share of profits$5.2B
- Reimbursement of commercialization-related expenses$729.3M
- Other revenue$702.6M
Leadership changes
From REGENERON PHARMACEUTICALS, INC.'s own filings, the day they're filed.
- Robert E. Landry · Chief Financial Officer · departureeff. 2023-09-08
- Marc Tessier-Lavigne · director · departureeff. 2023-09-01
- David P. Schenkein · director · appointment
Latest filings
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-07-06
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-04-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about REGENERON PHARMACEUTICALS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.